Divestments

Igenomix

A global leader in women’s health and reproductive genetic testing services for IVF clinics

The Company support c. 90,000 couples per year with a global footprint of 19 laboratories covering +80 countries.

  • Sector
    Healthcare
  • Country
    Spain
  • Responsible Advisor
    Vesa Koskinen
  • Fund
    EQT VIII
  • Entry
    2019
  • Web
  • Exit
    2021-11-30
  • Societal Contribution

  • 3Good health and well-being
  • 8Decent work and economic growth
  • 9Industry, innovation and infrastructure

About Igenomix
Igenomix’s vision is to become the worldwide reference in reproductive medicine and women’s health. Over the last decade, the Company has positioned itself as an innovation leader, supported by world-class R&D, and has established a global footprint with a network of 19 labs across 16 countries. Igenomix has also developed a diversified portfolio of IVF genetic services covering all phases of the reproductive cycle: i) preconception, ii) pre-implantation; and iii) pre-natal. The Company is headquartered in Valencia, Spain and employs +390 people, of which c.18% hold a PhD and have contributed to +440 scientific publications.

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of news
Preferred language
EQT logo
A purpose-driven global investment organization
© EQT AB 2021. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180